From the Departments of Plastic Surgery and Anesthesiology, The Ohio State University.
Plast Reconstr Surg. 2020 Mar;145(3):645-651. doi: 10.1097/PRS.0000000000006546.
Enhanced recovery after surgery (ERAS) protocols have known benefits in the inpatient setting, but little is known about their impact in the subsequent outpatient setting. On discharge, multimodal analgesia has been discontinued, nerve blocks and pain pumps have worn off, and patients enter a substantially different physical environment, potentially resulting in a rebound effect. The objective of this study was to investigate the effect of ERAS protocol implementation on outpatient opioid use and recovery.
Patients who underwent abdominally based microsurgical breast reconstruction before and after ERAS implementation were reviewed retrospectively. Ohio state law mandates that no more than 7 days of opioids may be prescribed at a time, with the details of all prescriptions recorded in a statewide reporting system, from which opioid use was determined.
A total of 105 patients met inclusion criteria, of which 46 (44 percent) were in the pre-ERAS group and 59 (56 percent) were in the ERAS group. Total outpatient morphine milligram equivalents used in the ERAS group were less than in the pre-ERAS group (337.5 morphine milligram equivalents versus 668.8 morphine milligram equivalents, respectively; p =0.016). This difference was specifically significant at postoperative week 1 (p =0.044), with gradual convergence over subsequent weeks. Although opioid use was significantly less in the ERAS group, pain scores in the ERAS group were comparable to those in the pre-ERAS group.
The benefits of ERAS protocols appear to extend into the outpatient setting, further supporting their use to facilitate recovery, and highlighting their potential role in helping to address the prescription opioid abuse problem.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
加速康复外科(ERAS)方案在住院患者中已被证实具有诸多益处,但对于其在随后的门诊环境中的影响却知之甚少。出院时,多模式镇痛已停止,神经阻滞和疼痛泵已失效,患者进入了一个截然不同的身体环境,这可能导致反弹效应。本研究旨在探讨 ERAS 方案实施对门诊阿片类药物使用和康复的影响。
回顾性分析了 ERAS 实施前后行腹部基底显微乳房重建的患者。俄亥俄州法律规定,每次开处方的阿片类药物不得超过 7 天,并将所有处方的详细信息记录在全州报告系统中,从而确定阿片类药物的使用情况。
共有 105 例患者符合纳入标准,其中 46 例(44%)在 ERAS 前组,59 例(56%)在 ERAS 组。ERAS 组门诊使用的吗啡等效剂量明显少于 ERAS 前组(分别为 337.5 吗啡等效剂量和 668.8 吗啡等效剂量;p=0.016)。这一差异在术后第 1 周特别显著(p=0.044),随后几周逐渐趋同。尽管 ERAS 组的阿片类药物使用量明显减少,但 ERAS 组的疼痛评分与 ERAS 前组相当。
ERAS 方案的益处似乎延伸到了门诊环境,进一步支持了其使用以促进康复,并强调了其在帮助解决处方阿片类药物滥用问题方面的潜在作用。
临床问题/证据水平:治疗性,III 级。